Clinical trials: Depression / Major Depressive Disorder
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Depressive Disorder, Major
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)
The purpose of this study to evaluate the efficacy of SAGE-217 in the treatment of participants with MDD.
- Trial name
- NCT04442490
- Testing
- SAGE-217
- Where
- 39 sites in United States
- Volunteers
- 543 people
- Sponsor
- Biogen
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Vilazodone for Treatment of Geriatric Depression
The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
- Trial name
- NCT01608295
- Testing
- Vilazodone; Viibryd, Paroxetine; Paxil
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Depression, Anxious Depression
Ketamine for Depression: An MRI Study
Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month.
- Conditions
- Depression, Anxious Depression, Major Depressive Disorder
- Trial name
- NCT02544607
- Testing
- Ketamine, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04533529
- Testing
- Seltorexant
- Where
- 122 sites in United States, Brazil and 9 more
- Volunteers
- 588 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing…
- Trial name
- NCT02720198
- Testing
- Levomilnacipran, Quetiapine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Major Depressive Disorder
Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression
The Researchers are going to gather information regarding the use of rTMS as a treatment for depression in adolescents with Major Depressive Disorder.
- Trial name
- NCT03363919
- Testing
- NeuroStar TMS Therapy® System, NeuroStar XPLOR®
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Major Depression, Fibromyalgia
A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia
In this pilot study, the PI proposes to include 20 African American participants with Fibromyalgia to explore the effect of r TMS on pain and depressive symptoms.
- Trial name
- TMS (NCT00523302)
- Testing
- Active TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Major Depression, Epilepsy
Lexapro for Major Depression in Patients With Epilepsy
The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms…
- Trial name
- NCT01244724
- Testing
- Lexapro
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Major Depressive Disorder
Imaging Dopamine Release in Depression
This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict…
- Trial name
- NCT02033369
- Testing
- Pramipexole
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD